Literature DB >> 20594769

A new formula for prostate cancer lymph node risk.

James B Yu1, Danil V Makarov, Cary Gross.   

Abstract

INTRODUCTION: The successful treatment of prostate cancer depends on the accurate estimation of the risk of regional lymph node (LN) involvement. The Roach formula (RF) has been criticized as overestimating LN risk. A modification of the RF has been attempted by other investigators using simplified adjustment ratios: the Nguyen formula (NF). METHODS AND MATERIALS: The National Cancer Institute Surveillance, Epidemiology, and End Results database was investigated for patients treated in 2004 through 2006 for whom at least 10 LN were examined at radical prostatectomy, cT1c or cT2 disease, and prostate-specific antigen (PSA) <26 ng/ml (N = 2,930). The Yale formula (YF) was derived from half of the sample (n = 1,460), and validated in the other half (n = 1,470).
RESULTS: We identified 2,930 patients. Only 4.6% of patients had LN+, and 72.6% had cT1c disease. Gleason (GS) 8-10 histology was found in 14.4% of patients. The YF for prediction of %LN+ risk is [GS - 5] × [PSA/3 + 1.5 × T], where T = 0, 1, and 2 for cT1c, cT2a, and cT2b/cT2c. Within each strata of predicted %LN+ risk, the actual %LN+ was closest to the YF. Using a >15% risk as an indicator of high-risk disease, the YF had increased sensitivity (39.0% vs. 13.6%) compared with the NF, without a significant reduction in specificity (94.9% vs. 98.8%). The NF was overly restrictive of the high-risk group, with only 2% of patients having a >15% risk of LN+ by that formula.
CONCLUSION: The YF performed better than the RF and NF and was best at differentiating patients at high risk for LN+ disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20594769     DOI: 10.1016/j.ijrobp.2010.01.068

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  [Radiotherapy of prostate cancer].

Authors:  S Krause; K Herfarth
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

2.  Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.

Authors:  Haoxin Zheng; Qi Miao; Yongkai Liu; Sohrab Afshari Mirak; Melina Hosseiny; Fabien Scalzo; Steven S Raman; Kyunghyun Sung
Journal:  Eur Radiol       Date:  2022-03-03       Impact factor: 7.034

3.  [Radiotherapy in the treatment of advanced and recurrent prostate cancer].

Authors:  D Böhmer
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

Review 4.  [Multimodal therapy of locally advanced prostate cancer].

Authors:  A Heidenreich; D Böhmer
Journal:  Urologe A       Date:  2016-03       Impact factor: 0.639

Review 5.  Radiotherapy and Hormone Treatment in Prostate Cancer.

Authors:  Dirk Böhmer; Manfred Wirth; Kurt Miller; Volker Budach; Axel Heidenreich; Thomas Wiegel
Journal:  Dtsch Arztebl Int       Date:  2016-04-08       Impact factor: 5.594

6.  68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer.

Authors:  Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Niels J Rupp; Martin Huellner; Michael Messerli; Jan Hendrik Rüschoff; Edwin E G W Ter Voert; Thomas Hermanns; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-14       Impact factor: 9.236

7.  The GP Score, a Simplified Formula (Bioptic Gleason Score Times Prostate Specific Antigen) as a Predictor for Biochemical Failure after Prostatectomy in Prostate Cancer.

Authors:  Norihito Soga; Yuji Ogura; Toshiaki Wakita; Takumi Kageyama; Jun Furusawa
Journal:  Curr Urol       Date:  2019-09-10

8.  Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer.

Authors:  K Schiller; M Devecka; T Maurer; M Eiber; J Gschwend; M Schwaiger; S E Combs; G Habl
Journal:  Radiat Oncol       Date:  2018-03-01       Impact factor: 3.481

9.  Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique.

Authors:  Gregor Habl; Gencay Hatiboglu; Lutz Edler; Matthias Uhl; Sonja Krause; Matthias Roethke; Heinz P Schlemmer; Boris Hadaschik; Juergen Debus; Klaus Herfarth
Journal:  BMC Cancer       Date:  2014-03-19       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.